Meta-analysis of Six Excimer Laser Platforms for Safety and Efficacy in Myopic Laser-assisted in situ Keratomileusis

摘要: Purpose: To compare excimer laser platform outcomes for myopic laser-assisted in situ keratomileusis (LASIK). Methods: A peer-reviewed literature search was conducted using the terms “myopia,” “LASIK,” and “outcomes.” Articles were selected based on inclusion/exclusion criteria. Data regarding Snellen visual acuity, refractive error ± 0.5 1.0 diopter (D) loss of best-corrected acuity extracted. US Food Drug Administration (FDA) approval studies used to fill any data gaps. Statistical analysis performed. Results: The Abbott outperformed other five multiple measures results at 1 3 months. Nidek lasers 20/16 level 6 Carl Zeiss/Meditec months outcome D. Alcon four safety category (least amount >2 line [BCVA]) month visit. There no significant differences between platforms, category, all time intervals. Conclusion: At times, fell within FDA guidelines bestcorrected acuity.